{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:59:04Z","timestamp":1792292344467,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.05.064","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T03:38:07Z","timestamp":1590377887000},"page":"4783-4791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines"],"prefix":"10.1016","volume":"38","author":[{"given":"Paul-Henri","family":"Lambert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-8367","authenticated-orcid":false,"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3871-918X","authenticated-orcid":false,"given":"Cornelia L.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud M.","family":"Didierlaurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha D.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah C.","family":"Molrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-2354","authenticated-orcid":false,"given":"Stanley","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Picard-Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-1232","authenticated-orcid":false,"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob P.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2020.05.064_b0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.05.064_b0010","unstructured":"COVID-19 Data Center. 2020, Johns Hopkins Coronavirus Resource Center."},{"key":"10.1016\/j.vaccine.2020.05.064_b0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.064_b0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.064_b0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2020.05.064_b0030","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.064_b0035","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/jvi.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells","volume":"66","author":"Connors","year":"1992","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.05.064_b0045","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-Induced Enhanced Disease Illness","volume":"9","author":"Smatti","year":"2018","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.064_b0050","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1128\/JVI.79.9.5833-5838.2005","article-title":"Aged BALB\/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans","volume":"79","author":"Roberts","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.064_b0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/JVI.05957-11","article-title":"Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease","volume":"86","author":"Frieman","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030005","article-title":"A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice","volume":"3","author":"Roberts","year":"2007","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2007.12.032","article-title":"The SARS-CoV ferret model in an infection-challenge study","volume":"374","author":"Chu","year":"2008","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/JVI.79.1.503-511.2005","article-title":"Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters","volume":"79","author":"Roberts","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.064_b0075","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.virusres.2007.01.021","article-title":"Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease","volume":"133","author":"Enjuanes","year":"2008","journal-title":"Virus Res"},{"issue":"6982","key":"10.1016\/j.vaccine.2020.05.064_b0085","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.064_b0090","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","article-title":"Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Kim","year":"2004","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2020.05.064_b0095","doi-asserted-by":"crossref","first-page":"E3119","DOI":"10.1073\/pnas.1619109114","article-title":"Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.05.064_b0100","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1038\/nmicrobiol.2016.226","article-title":"A mouse model for MERS coronavirus-induced acute respiratory distress syndrome","volume":"2","author":"Cockrell","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.virol.2017.12.006","article-title":"Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease","volume":"517","author":"Douglas","year":"2018","journal-title":"Virology"},{"issue":"14","key":"10.1016\/j.vaccine.2020.05.064_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan5393","article-title":"Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses","volume":"2","author":"Zhao","year":"2017","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2004.09.030","article-title":"Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys","volume":"330","author":"McAuliffe","year":"2004","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.064_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000756","article-title":"Exacerbated innate host response to SARS-CoV in aged non-human primates","volume":"6","author":"Smits","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.05.064_b0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2016.01.004","article-title":"3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3\/2012","volume":"490","author":"Johnson","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.05.064_b0130","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.virol.2015.07.013","article-title":"Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3\/2012 or MERS-CoV EMC\/2012 isolates does not result in lethal disease","volume":"485","author":"Johnson","year":"2015","journal-title":"Virology"},{"issue":"20","key":"10.1016\/j.vaccine.2020.05.064_b0135","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-11-82","article-title":"Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus","volume":"11","author":"Yip","year":"2014","journal-title":"Virol J"},{"issue":"23","key":"10.1016\/j.vaccine.2020.05.064_b0145","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.064_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JVI.01805-10","article-title":"Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus","volume":"85","author":"Sheahan","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.064_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.064_b0165","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2020.05.064_b0170","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J Virol"},{"issue":"49\u201350","key":"10.1016\/j.vaccine.2020.05.064_b0175","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1016\/j.vaccine.2006.07.009","article-title":"Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25\u201326 August 2005, London, UK","volume":"24","author":"Roberts","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.064_b0180","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.064_b0185","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/infdis\/jiz137","article-title":"A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model","volume":"220","author":"Hashem","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.064_b0190","first-page":"4(4)","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.064_b0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.064_b0200","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.0c00148","article-title":"Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates","author":"Wang","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.05.064_b0205","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.vaccine.2005.06.038","article-title":"Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine","volume":"24","author":"Qin","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.064_b0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.064_b0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ame2.12108","article-title":"Age-related rhesus macaque models of COVID-19","volume":"3","author":"Yu","year":"2020","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.vaccine.2020.05.064_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","author":"Rockx","year":"2020","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.vaccine.2020.05.064_b0230","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6483","key":"10.1016\/j.vaccine.2020.05.064_b0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.05.064_b0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","article-title":"Towards an evidence based approach for the development of adjuvanted vaccines","volume":"47","author":"O'Hagan","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"85","key":"10.1016\/j.vaccine.2020.05.064_b0245","doi-asserted-by":"crossref","first-page":"p. 85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2020.05.064_b0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-018-0076-2","article-title":"AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization","volume":"3","author":"Khurana","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.064_b0255","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1172\/JCI129520","article-title":"Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination","volume":"130","author":"Boudreau","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.05.064_b0260","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/1471-2334-14-425","article-title":"Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older","volume":"14","author":"Couch","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.064_b0265","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0270","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.064_b0275","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.064_b0280","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","article-title":"Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma","volume":"171","author":"Sun","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0285","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0290","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.05.064_b0295","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.smim.2018.08.001","article-title":"Systems analysis of human vaccine adjuvants","volume":"39","author":"Harandi","year":"2018","journal-title":"Semin Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2020.05.064_b0300","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030709X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030709X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:21Z","timestamp":1759401801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2030709X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":60,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X2030709X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}